1 |
Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-2047.
DOI
ScienceOn
|
2 |
Ruilope LM. Renal function and cardiovascular risk in hypertensive patients. J Hypertens 2005;23:1787-1788.
DOI
ScienceOn
|
3 |
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-S266.
|
4 |
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
DOI
|
5 |
Shin SY, Kwon MJ, Park H, Woo HY. Comparison of chronic kidney disease prevalence examined by the chronic kidney disease epidemiology collaboration equation with that by the modification of diet in renal disease equation in Korean adult population. J Clin Lab Anal 2014 Feb 27 [Epub]. http://dx.doi.org/10.1002/ jcla.21688.
|
6 |
Holick MF. Vitamin D def iciency. N Engl J Med 2007;357:266-281.
DOI
ScienceOn
|
7 |
LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005;45:1026-1033.
DOI
ScienceOn
|
8 |
Urena-Torres P, Metzger M, Haymann JP, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis 2011;58:544-553.
DOI
ScienceOn
|
9 |
Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009;76:977-983.
DOI
ScienceOn
|
10 |
Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta- analysis of prospective studies. Am J Kidney Dis 2011;58:374-382.
DOI
ScienceOn
|
11 |
Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 2013;14:199.
DOI
ScienceOn
|
12 |
Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:F8-F28.
DOI
ScienceOn
|
13 |
Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.
DOI
ScienceOn
|
14 |
Mirkovic K, van den Born J, Navis G, de Borst MH. Vitamin D in chronic kidney disease: new potential for intervention. Curr Drug Targets 2011;12:42-53.
DOI
ScienceOn
|
15 |
Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-2072.
DOI
ScienceOn
|
16 |
Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 2004;215:31-38.
DOI
ScienceOn
|
17 |
Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010;95:471-478.
DOI
ScienceOn
|
18 |
Ohyama Y, Ozono K, Uchida M, et al. Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 1994;269:10545-10550.
|
19 |
Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43.
DOI
ScienceOn
|
20 |
Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011;79:715-729.
DOI
ScienceOn
|
21 |
Hilpert J, Wogensen L, Thykjaer T, et al. Expression prof iling conf irms the role of endocytic receptor megalin in renal vitamin D3 metabolism. Kidney Int 2002;62:1672-1681.
DOI
ScienceOn
|
22 |
Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999;96:507-515.
DOI
ScienceOn
|
23 |
Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate f ibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005;146:5358-5364.
DOI
ScienceOn
|
24 |
Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999;155:1361-1370.
DOI
ScienceOn
|
25 |
Liu W, Yu WR, Carling T, et al. Regulation of gp330/ megalin expression by vitamins A and D. Eur J Clin Invest 1998;28:100-107.
DOI
ScienceOn
|
26 |
Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-435.
|
27 |
Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-1946.
DOI
ScienceOn
|
28 |
Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-2279.
DOI
ScienceOn
|
29 |
Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 1973;154:566-574.
DOI
ScienceOn
|
30 |
Kuro-o M. Klotho and the aging process. Korean J Intern Med 2011;26:113-122.
DOI
ScienceOn
|
31 |
Usatii M, Rousseau L, Demers C, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia- induced 1,25(OH)2D synthesis. Kidney Int 2007;72:1330-1335.
DOI
ScienceOn
|
32 |
Hsu CH, Patel S. Uremic plasma contains factors inhibiting 1 alpha-hydroxylase activity. J Am Soc Nephrol 1992;3:947-952.
|
33 |
Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012;302:F647-F657.
DOI
|
34 |
Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008;19:1741-1752.
DOI
ScienceOn
|
35 |
Tan X, Li Y, Liu Y. Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol 2007;103:491-496.
DOI
ScienceOn
|
36 |
Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010;77:1000-1009.
DOI
ScienceOn
|
37 |
Park JW, Bae EH, Kim IJ, et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol 2010;298:F301-F313.
DOI
ScienceOn
|
38 |
Park JW, Bae EH, Kim IJ, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int 2010;77:1076-1085.
DOI
ScienceOn
|
39 |
Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696-1705.
DOI
ScienceOn
|
40 |
He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:90-103.
DOI
ScienceOn
|
41 |
Garcia IM, Altamirano L, Mazzei L, et al. Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy. Am J Physiol Renal Physiol 2012;302:F1595-F1605.
DOI
|
42 |
Panichi V, Migliori M, Taccola D, et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001;60:87-95.
DOI
ScienceOn
|
43 |
Xiao H, Shi W, Liu S, et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 2009;30:34-43.
DOI
ScienceOn
|
44 |
Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001;158:1733-1741.
DOI
ScienceOn
|
45 |
Park JW, Cho JW, Joo SY, et al. Paricalcitol prevents cisplatin- induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012;683:301-309.
DOI
ScienceOn
|
46 |
Suh SH, Lee KE, Park JW, et al. Antiapoptotic effect of paricalcitol in gentamicin-induced kidney injury. Korean J Physiol Pharmacol 2013;17:435-440.
DOI
ScienceOn
|
47 |
Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004;286:F526-F533.
DOI
ScienceOn
|
48 |
Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-1402.
DOI
ScienceOn
|
49 |
Zhang Y, Deb DK, Kong J, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009;297:F791-F801.
DOI
ScienceOn
|
50 |
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-238.
DOI
ScienceOn
|
51 |
Kim CS, Joo SY, Lee KE, et al. Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inf lammation and epithelial- mesenchymal transition in human renal proximal tubular epithelial cells. PLoS One 2013;8:e63186.
DOI
ScienceOn
|
52 |
Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial f ibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112:1486-1494.
DOI
|
53 |
Rampanelli E, Rouschop K, Teske GJ, Claessen N, Leemans JC, Florquin S. CD44v3-v10 reduces the profibrotic effects of TGF-beta1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy. Am J Physiol Renal Physiol 2013;305:F1445-F1454.
DOI
ScienceOn
|
54 |
Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17:3382-3393.
DOI
ScienceOn
|
55 |
Drueke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens 2005;14:343-349.
DOI
ScienceOn
|
56 |
Okada H, Kalluri R. Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 2005;5:467-474.
DOI
ScienceOn
|
57 |
Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010;21:1247-1253.
DOI
ScienceOn
|
58 |
Yoon HE, Yang CW. Established and newly proposed mechanisms of chronic cyclosporine nephropathy. Korean J Intern Med 2009;24:81-92.
DOI
ScienceOn
|
59 |
Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11:152-176.
|
60 |
Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001;59:415-424.
DOI
ScienceOn
|
61 |
Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int 2011;80:29-40.
DOI
ScienceOn
|
62 |
Jiang M, Wei Q, Wang J, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006;25:4056-4066.
DOI
ScienceOn
|
63 |
Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 2012;60:139-156.
DOI
ScienceOn
|
64 |
Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38.
DOI
ScienceOn
|
65 |
Tourigny A, Charbonneau F, Xing P, et al. CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. PLoS One 2012;7:e48652.
DOI
|
66 |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):S1-S130.
|
67 |
Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28.
DOI
|
68 |
Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 2009;4:1523-1528.
DOI
ScienceOn
|
69 |
Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
DOI
ScienceOn
|
70 |
Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70:351-357.
DOI
ScienceOn
|
71 |
Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-184.
DOI
ScienceOn
|
72 |
de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50:69-77.
DOI
ScienceOn
|
73 |
Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75:88-95.
DOI
ScienceOn
|
74 |
de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-1551.
DOI
ScienceOn
|
75 |
Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011;32:1493-1499.
DOI
ScienceOn
|
76 |
Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540-1546.
DOI
ScienceOn
|
77 |
Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inf lammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011;21:295-302.
DOI
ScienceOn
|
78 |
de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 2013;24:1863-1871.
DOI
|
79 |
Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
DOI
ScienceOn
|
80 |
Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial. J Am Soc Nephrol 2014;25:175-186.
DOI
ScienceOn
|
81 |
Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577-1588.
DOI
|
82 |
Bae S, Yalamarti B, Ke Q, et al. Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovasc Res 2011;91:632-639.
DOI
ScienceOn
|
83 |
Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2012;59:67-74.
DOI
ScienceOn
|
84 |
Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-684.
DOI
ScienceOn
|
85 |
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393- 4408.
DOI
ScienceOn
|
86 |
Alvarez JA, Zughaier SM, Law J, et al. Effects of highdose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 2013;67:264-269.
DOI
ScienceOn
|